Trial Profile

DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 19 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapagliflozin (Primary)
Indications Cardiovascular disorders; Kidney disorders; Type 2 diabetes mellitus
Focus Biomarker; Therapeutic Use
Acronyms DAPA-SWEET

Most Recent Events

15 May 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
15 May 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
12 Feb 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com